Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

66.16USD
24 Feb 2017
Change (% chg)

$0.31 (+0.47%)
Prev Close
$65.85
Open
$65.65
Day's High
$66.16
Day's Low
$65.63
Volume
8,444,253
Avg. Vol
11,025,544
52-wk High
$66.16
52-wk Low
$49.63

Latest Key Developments (Source: Significant Developments)

European Commission approves Keytruda for first-line treatment of patients with metastatic non-small cell lung cancer
Tuesday, 31 Jan 2017 04:00pm EST 

Merck & Co Inc : European Commission approves Keytruda® (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-l1 expression with no EGFR or ALK positive tumor mutations .Merck & Co Inc- Approval based on Phase 3 data,demonstrated superior overall survival,progression-free survival with Keytruda compared to chemotherapy.  Full Article

Merck announces license agreement resolving Keytruda patent litigation
Friday, 20 Jan 2017 04:01pm EST 

Merck & Co Inc - : Merck announces settlement and license agreement resolving Keytruda® (pembrolizumab) patent litigation . Under settlement and license agreement, company will make a one-time payment of $625 million to Bristol-Myers Squibb . Parties also agreed to dismiss all claims in relevant legal proceedings . $625 million payment will be recorded in company's fourth-quarter and full-year 2016 results . The expense will be excluded from merck's non-gaap results .Parties also agreed to dismiss all claims in relevant legal proceedings..  Full Article

Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck
Friday, 20 Jan 2017 04:01pm EST 

Bristol-myers Squibb Co - : Bristol-Myers Squibb and Ono Pharmaceutical Company enter settlement and license agreement with merck to resolve PD-1 antibody patent litigation . Merck to pay Bristol-Myers Squibb and Ono royalties on global sales of keytruda through 2026, and lump-sum payment of $625 million . Agreement will result in dismissal with prejudice of all patent litigation between companies pertaining to keytruda . Agreement ends all global patent-infringement litigation against Merck's sale of keytruda . Merck is also obligated to pay ongoing royalties on global sales of keytruda of 6.5% from Jan 1, 2017 through Dec 31, 2023 . Companies have also granted certain rights to each other under their respective patent portfolios pertaining to PD-1 . Merck is also obligated to pay ongoing royalties on global sales of keytruda 2.5% from January 1, 2024 through Dec 31, 2026 . Royalties pertaining to PD-1 to be shared between Bristol-Myers Squibb and Ono in a 75/25 percent allocation, respectively .Royalties will be shared between Bristol-Myers Squibb and Ono in a 75/25 percent allocation, respectively.  Full Article

Merck & Co Inc gets FDA acceptance of supplemental biologics license application for Keytruda in combination with chemotherapy
Tuesday, 10 Jan 2017 04:06pm EST 

Merck & Co Inc : Merck receives fda acceptance of supplemental biologics license application for keytruda® (pembrolizumab) in combination with chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer . Merck & co inc - fda granted priority review with a pdufa, or target action, date of may 10, 2017 .Merck & Co Inc- SBLA will be reviewed under fda's accelerated approval program.  Full Article

Drugmakers trade group says government mandates wrong way to address drug costs
Wednesday, 7 Dec 2016 12:15pm EST 

U.S. drugmakers trade group PhRMA, in response to President-Elect Trump statement that he will bring down drug prices: PhRMA says government mandates, interventions are not right means of addressing prescription drug costs . Trade group says looking forward to working with Trump Administration next year to enhance competitive private market, ensure drug access .Trade group statement follows comment from Trump in Time Magazine interview that he will "bring down drug prices".  Full Article

Merck presents updated findings from Keytruda
Monday, 5 Dec 2016 10:42am EST 

Merck & Co Inc : Updated Keytruda (Pembrolizumab) findings in patients with relapsed or refractory primary mediastinal large B-cell lymphoma presented at 58th annual meeting of the American society of Hematology . Data from keynote-013 demonstrated overall response rate of 41 percent, with 86 percent of responses ongoing at time of analysis . anti-pd-1 therapy, achieved orr of 41 percent with follow-up of up to 27 months in patients with relapsed or refractory PMBCL .there were no discontinuations or treatment-related deaths due to adverse events in keynote-013 study.  Full Article

Merck CEO says importing drugs from outside U.S. not possible
Thursday, 1 Dec 2016 11:18am EST 

Merck & Co : CEO Kenneth Frazier says does not think importing cheaper drugs from outside U.S. possible - CNBC interview . Merck CEO Frazier says importing drugs from outside U.S. "actually a dangerous concept" - CNBC interview .Merck CEO Frazier says FDA cannot ensure safety of imported drugs - CNBC interview.  Full Article

Merck raises quarterly dividend to $0.47/share from $0.46/share
Tuesday, 22 Nov 2016 01:22pm EST 

Merck : Merck announces increased quarterly dividend . Sets quarterly dividend of $0.47 per share .Increased quarterly dividend to $0.47 per share, up $0.01 from $0.46 per outstanding share paid last quarter.  Full Article

Genexine entered into a clinical research collaboration with Merck & Co
Wednesday, 16 Nov 2016 08:00am EST 

Genexine Inc <095700.KQ> : Genexine - Entered into a clinical research collaboration with Merck & Co., Inc . Genexine-Research collaboration for assessment of co's GX-188E, HPV therapeutic DNA vaccine, in combination with MSD's anti-PD-1 therapy, Keytruda .Genexine - Additional details were not disclosed..  Full Article

OpGen collaborates with Merck to develop rapid diagnostics and informatics tools to help combat antimicrobial resistance
Monday, 14 Nov 2016 07:00am EST 

Merck & Co Inc :OpGen Inc - entered into research collaboration with Merck to develop rapid diagnostics, it products to help combat threat of antimicrobial resistance.  Full Article

More From Around the Web

BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases

* In first phase 3 trial, Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects